137915-13-0

Usage

Uses

Used in Pharmaceutical Industry:
S-[N-(3-PHENYLPROPYL)(THIOCARBAMOYL)]-L-CYSTEINE is used as a potential anticarcinogenic compound for promoting the detoxification of carcinogens in the body. It has demonstrated the ability to induce Glutathione S-transerase activity in target organs of mice without causing any apparent toxic effects, making it a promising candidate for further research and development in cancer prevention and treatment.
Used in Research and Development:
In addition to its potential pharmaceutical applications, S-[N-(3-PHENYLPROPYL)(THIOCARBAMOYL)]-L-CYSTEINE can be utilized in research and development for understanding the mechanisms of carcinogen detoxification and the role of Glutathione S-transerase in cancer prevention. This knowledge can contribute to the development of new therapeutic strategies and drug candidates for cancer treatment.
Used in Chemical Synthesis:
As a white solid with unique chemical properties, S-[N-(3-PHENYLPROPYL)(THIOCARBAMOYL)]-L-CYSTEINE may also find applications in chemical synthesis, particularly in the development of new compounds with potential biological activities. Its synthesis and modification can be explored for creating novel molecules with improved properties and applications in various fields, including pharmaceuticals, materials science, and environmental science.

InChI:InChI=1/C13H18N2O2S2/c14-11(12(16)17)9-19-13(18)15-8-4-7-10-5-2-1-3-6-10/h1-3,5-6,11H,4,7-9,14H2,(H,15,18)(H,16,17)/t11-/m0/s1

Upstream product

• 2627-27-2 3-phenylpropyl isothiocyanate 
• 52-89-1 l-cysteine hydrochloride 
• 52-90-4 L-Cysteine 

Relevant academic research and scientific papers

Phenylalkyl Isothiocyanate-Cysteine Conjugates as Glutathione S-Transferase Stimulating Agents

The develop analogues of phenylalkyl isothiocyanate with less toxicity and better biological activity, two water-soluble phenylalkyl isothiocyanate-cysteine conjugates, S--L-cysteine (1) and S--L

Inhibition of human leukaemia 60 cell growth by mercapturic acid metabolites of phenylethyl isothiocyanate

Mercapturic acid pathway metabolites of phenylethyl isothiocyanate inhibited the growth of human leukaemia 60 (HL60) cells in vitro. The adduct with L-cysteine, S-(N-phenylethylthiocarbamoyl)cysteine, was the most potent with strong antileukaemic activity: the median growth inhibitory concentration (GC50) value was 336 ± 1 nM (N = 18) compared with GC50 values of the precursor formed from dietary glucosinolates, phenylethyl isothiocyanate, 1.49 ± 0.01 μM (N = 8), and the initial mercapturic acid pathway metabolite S-(N-phenylethylthiocarbamoyl)glutathione 5.46 ± 0.36 μM (N = 18). S-(N-Benzylthiocarbamoyl)cysteine and S-(N-phenylpropylthiocarbamoyl)cysteine also had antiproliferative activity but S-(N-phenylethylthiocarbamoyl)cysteine was the most potent compound studied. The latter induced DNA fragmentation in HL60 cells but DNA laddering characteristic of apoptosis was not observed. It had low toxicity to corresponding differentiated cells, neutrophils, in culture, and therefore the cytotoxicity had selectivity for leukaemia cells. The antiproliferative activity of S-(N-phenylethylthiocarbamoyl)cysteine was lost during preincubation with culture medium, attributed to S-thiocarbamoyl transfer to serum proteins, which may decrease its effectiveness in vivo. The antiproliferative activity of S-(N-phenylalkylthiocarbamoyl)cysteine derivatives, by inhibiting tumour growth in pre-clinical development, may contribute to the association of decreased cancer incidence with dietary glucosinolate consumption.